Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCB186748 + mFOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
INCB186748 + mFOLFIRINOX is an investigational combination regimen evaluated in clinical trials for patients with advanced or metastatic solid tumors—particularly pancreatic ductal adenocarcinoma (PDAC)—that harbor the KRAS G12D mutation. - **INCB186748** is a small molecule oral inhibitor designed to selectively target the KRAS G12D mutated protein, thereby inhibiting cellular pathways that drive tumor growth in KRAS G12D-mutant cancers[6]. - **mFOLFIRINOX** (modified FOLFIRINOX) is a cytotoxic chemotherapy regimen comprised of fluorouracil (5FU), leucovorin (folinic acid), irinotecan, and oxaliplatin, frequently used as first-line treatment in metastatic pancreatic cancer. It works by interfering with DNA synthesis and cell division in rapidly dividing tumor cells[1][3][5]. The regimen is currently studied in clinical trials as a combination therapy in PDAC and solid tumors with specified genetic alterations, with the aim of improving efficacy over chemotherapy alone[4][2].
- Other names
- MFOLFIRINOXmodified FOLFIRINOX
02
Targets
TOP1 (DNA Topoisomerase I)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)DNA
Beyond the preview
Go deeper on INCB186748 + mFOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCB186748 + mFOLFIRINOX.